Patents by Inventor William C. Fanslow
William C. Fanslow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7833697Abstract: The present invention provides stem cells characterized as having the ability to renew and the ability to give rise to endothelial and/or endothelial-like cells, methods of isolating such stem cells and methods of use thereof. Also provided are progeny cells derived from the stem cells of the invention.Type: GrantFiled: December 20, 2002Date of Patent: November 16, 2010Assignee: Immunex CorporationInventors: William C. Fanslow, III, Anne-Marie C. Rousseau, Thomas O. Daniel
-
Patent number: 7829675Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: January 16, 2009Date of Patent: November 9, 2010Assignee: Immunex CorporationInventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Patent number: 7807796Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: August 4, 2008Date of Patent: October 5, 2010Assignee: Immunex CorporationInventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage
-
Publication number: 20100233186Abstract: Isolated receptors for CTLA-8, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to inhibit an immune response.Type: ApplicationFiled: March 11, 2010Publication date: September 16, 2010Inventors: ZHENGBIN YAO, MELANIE K. SPRIGGS, WILLIAM C. FANSLOW
-
Publication number: 20090324597Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: ApplicationFiled: August 4, 2008Publication date: December 31, 2009Applicant: IMMUNEX CORPORATIONInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Publication number: 20090263383Abstract: The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD148. Compositions of the invention include: anti-CD148 antibodies, antigen binding regions of anti-CD148 antibodies, polynucleotides encoding anti-CD 148 antibodies or binding regions thereof, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions is also provided.Type: ApplicationFiled: February 27, 2008Publication date: October 22, 2009Applicant: Amgen Inc.Inventors: James F. Smothers, William C. Fanslow, III, Revital Kariv
-
Publication number: 20090137036Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: ApplicationFiled: January 16, 2009Publication date: May 28, 2009Inventors: KRISTINE M. KIM, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Publication number: 20090068737Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.Type: ApplicationFiled: September 19, 2007Publication date: March 12, 2009Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
-
Patent number: 7495086Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: October 22, 2004Date of Patent: February 24, 2009Assignee: Immunex CorporationInventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
-
Patent number: 7449555Abstract: Anti-CD148 antibodies and antigen-binding regions thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding regions, are described. Also described are methods of using such antibodies and antigen-binding regions to bind CD148 epitopes and activate CD148 function, such as inhibition of angiogenesis. Epitopes that can be used to activate CD148 function and anti-angiogenesis activity are also described, as well as methods of identifying compounds that can bind them.Type: GrantFiled: April 22, 2005Date of Patent: November 11, 2008Assignee: Amgen Inc.Inventors: William C. Fanslow, III, Revital Kariv, James F. Smothers
-
Patent number: 7432237Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.Type: GrantFiled: December 18, 2003Date of Patent: October 7, 2008Assignee: Immunex CorporationInventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
-
Patent number: 7427669Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: December 13, 2006Date of Patent: September 23, 2008Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 7405270Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.Type: GrantFiled: July 19, 2002Date of Patent: July 29, 2008Assignee: Immunex CorporationInventors: Richard J. Armitage, William C. Fanslow, III, Melanie K. Spriggs
-
Patent number: 7309489Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.Type: GrantFiled: May 28, 1999Date of Patent: December 18, 2007Assignee: IMMUNEX CorporationInventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
-
Patent number: 7273843Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.Type: GrantFiled: December 18, 2003Date of Patent: September 25, 2007Assignee: Immunex CorporationInventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
-
Patent number: 7193058Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: GrantFiled: June 23, 2004Date of Patent: March 20, 2007Assignee: Immunex CorporationInventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
-
Patent number: 7175849Abstract: This invention relates to nectin polypeptides and polynucleotides, to methods of making such polypeptides and polynucleotides, and to methods of using such polypeptides and polynucleotides to modulate cell adhesion, cell migration, and angiogenesis, to treat conditions related to cell adhesion including endothelial and epithelial cell proliferation, migration, and barrier function, and to identify agents that alter nectin polypeptide activities.Type: GrantFiled: October 5, 2001Date of Patent: February 13, 2007Assignee: Immunex CorporationInventors: Peter R Baum, William C Fanslow, III, Timothy E Lofton, Eric A Sorensen, Adel Youakim
-
Patent number: 7074408Abstract: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.Type: GrantFiled: February 23, 2001Date of Patent: July 11, 2006Assignee: Immunex CorporationInventors: William C. Fanslow, III, Douglas P. Cerretti, Kurt M. Poindexter, Roy A. Black
-
Patent number: 7067475Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.Type: GrantFiled: February 3, 2003Date of Patent: June 27, 2006Assignee: Immunex CorporationInventors: Douglas P. Cerretti, Luis G. Borges, William C. Fanslow, III
-
Publication number: 20040235058Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: ApplicationFiled: June 23, 2004Publication date: November 25, 2004Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, Marek Kubin, Richard Jeffrey Armitage